Please select the eligibility criteria that correspond to the clinical trial below.
Title: Prospective, Randomized, Double-Blind, Placebo-Controlled Trial of Erythropoietin in Patients With ST-Segment-Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention (REVIVAL-3)
Brief Summary: The purpose of this study is to determine whether erythropoietin is superior to placebo with respect to left ventricular ejection fraction in patients with ST-elevation myocardial infarction undergoing percutaneous coronary intervention.


Options:
A: Inclusion Criteria:

* preoperative risk factors for AKI and scheduled for complex valvular heart operations
* Enrolled criteria for high risk of AKI were patients with more than 2 of bellows: female, serum creatinine \>1.2 mg/dl, preoperative A-fib, GFR \< 60 ml/min, NYHA class IV, HTN, DM, age \> 65 years, peripheral vascular disease.
* Complex valvular heart operations were defined as double-valve surgery, combined valve and coronary artery bypass grafting procedures, Bentall operation, combined mitral valve surgery and tricuspid annuloplasty or reoperation.

Exclusion Criteria:

* Patients with preexisting uncontrolled hypertension (diastolic blood pressure \> 100 mmHg), immunosuppression, history of thromboembolism, malignant disease, seizure, liver dysfunction, renal impairment (serum creatinine \> 2 mg/dL), and drug or alcohol abuse were excluded.
B: Inclusion Criteria:

* Patients with ST-Segment elevation myocardial infarction \<24 h from pain onset
* Successful primary PCI and left ventricular ejection fraction \<50%
* Informed, written consent
* In women with childbearing potential a pregnancy test is mandatory

Exclusion Criteria:

* Age \< 18 and \> 80 years
* Cardiogenic shock
* pericarditis
* thrombolysis for the index infarction
* malignancies/other comorbid conditions with life expectancy \< 1 year
* previous myocardial infarction
* planned staged PCI or prior PCI within 30 days from index procedure
* uncontrolled hypertension \>160/100mmHg unresponsive to therapy
* epilepsy
* active bleeding; bleeding diathesis; history of gastrointestinal or genitourinary bleeding, recent trauma or major surgery \< 1 month; history of intracranial bleeding or structural abnormalities; suspected aortic dissection; patient's refusal to blood transfusion
* hematologic disorders such as essential thrombocytosis, megakaryoblastic leukemia, polycythemia vera
* relevant hematologic deviations: hemoglobin \< 100 g/l or hemoglobin \> 160 g/l platelet count \< 100 x 10\^9 cells/l or platelet count \> 600 x 10\^9 cells/l
* any contraindication to magnetic resonance imaging: electronically, magnetically and mechanically activated implants such as cardiac pacemakers, automatic cardioverter defibrillators, joint prostheses, surgical/vascular clips/ hearing aids, neurostimulators, infusion pumps etc metallic splinters in the eye ferromagnetic haemostatic clips in the central nervous system cochlear implants lead wires or similar wires prosthetic heart valves, if dehiscence is suspected non-ferromagnetic stapedial implants, hemostatic clips
* glomerular filtration rate \< 30 ml/min or serum creatinine \> 30 mg/l or dependence on renal dialysis
* chronic liver disease with GOT \> 5-fold over the normal range
* allergy to erythropoietin/true anaphylaxis after prior exposure to contrast media
* phenylketonuria
* previous enrollment in this trial
* women who are known to be pregnant, who are of childbearing potential and test positive for pregnancy, who have given birth within the last 90 days, who are breastfeeding
* patient's inability to fully cooperate with the study protocol
* other contraindication according to the summary of product characteristics of recombinant human erythropoietin beta (NeoRecormon®)
C: Inclusion Criteria:

* Are ≥ 15 to ≤ 65 years of age
* Are \< 24 hours since primary traumatic injury
* Are expected to stay ≥ 48 hours
* Have a haemoglobin not exceeding the upper limit of the applicable normal (ULN) reference range in clinical use at the treating institution
* Have written informed consent from legal surrogate

Exclusion Criteria:

* GCS = 3 and fixed dilated pupils
* History of DVT, PE or other thromboembolic event
* A chronic hypercoagulable disorder, including known malignancy
* Treatment with EPO in the last 30 days
* First dose of study drug unable to be given within 24 hours of primary injury
* Pregnancy or lactation or 3 months post partum
* Uncontrolled hypertension (systolic blood pressure of \>200 mm Hg or diastolic blood pressure of \>110 mm Hg)
* Acute myocardial infarct
* Expected to die imminently (\< 24 hours)
* Inability to perform lower limb ultrasounds
* Known sensitivity to mammalian cell derived products
* Hypersensitivity to the active substance or to any of the additives
* Pure red cell aplasia (PRCA)
* End stage renal failure (receives chronic dialysis)
* Severe pre-existing physical or mental disability or severe co-morbidity that may interfere with the assessment of outcome
* Spinal cord injury
* Treatment with any investigational drug within 30 days before enrolment
* The treating physician believes it is not in the best interest of the patient to be randomised to this trial
D: Inclusion Criteria:

* Ischemic stroke in the middle cerebral artery territory
* Clearly defined time of onset
* Confirmed by MRI (DWI, Flair)
* NIH Stroke Scale ≥ 5
* Age \> 18 years
* Treatment within 6h after onset of symptoms
* Informed consent by patient, relatives or independent physician
* Life expectancy \> 90 days

Exclusion Criteria:

* Coma or precoma (level of consciousness ≥ 2 in NIH Stroke Scale)
* Previous stroke within the same territory
* Intracranial or subarachnoidal hemorrhage
* Traumatic brain injury or brain operation within the last 4 weeks
* Neoplasia, septic embolism, infectious endocarditis
* MRI contraindications
* Renal failure (i.e. dependent on dialysis)
* Known malignant/life-threatening disease
* Known myeloproliferative disorder, polycythemia
* Known allergy or antibodies against erythropoietin
* Participation in other intervention trials
* Pregnancy

Answer: B